Pay in 4 interest-free payments of $5.86 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
These new options will likely increase competition and further drive down prices for individuals and insurers
Key points The results of the EMPA-REG OUTCOME trial fundamentally transformed cardiovascularkidneymetabolic medicine by demonstrating that a glucose-lowering drug (a sodiumglucose cotransporter 2 (SGLT2) inhibitor) could reduce cardiovascular death, hospitalization for heart failure and the progression of chronic kidney disease in patients with type 2 diabetes mellitus
Fungal cell factories for efficient and sustainable production of proteins and peptides
This question comes up constantly, and the honest answer depends on individual factors
US$ 27.39
US$ 29.57
US$ 28.35
US$ 25.54
